Literature DB >> 21292041

Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type.

Tanya Pinto1, Krista L Lanctôt, Nathan Herrmann.   

Abstract

Behavioral and psychological symptoms of dementia (BPSD) include agitation, aberrant motor behavior, anxiety, elation, irritability, depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite impairment. These symptoms have adverse consequences for patients and caregivers, such as greater impairment in activities of daily living, worsening quality of life and earlier institutionalization. While the etiology of BPSD has not been clearly delineated, studies assessing the benefits of acetylcholinesterase inhibitors on BPSD suggest that some of the neuropsychiatric symptoms of dementia such as agitation, apathy and psychosis may represent a specific central cholinergic deficiency syndrome. Biochemical and neuroimaging studies of BPSD in Alzheimer's patients support these pharmacological data. This review discusses the literature describing the association between cholinergic deficiency and manifestations of BPSD.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21292041     DOI: 10.1016/j.arr.2011.01.003

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  32 in total

Review 1.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.

Authors:  Florian G Metzger; Ann-Christine Ehlis; Florian B Haeussinger; Andreas J Fallgatter; Katja Hagen
Journal:  Psychopharmacology (Berl)       Date:  2015-09-11       Impact factor: 4.530

Review 3.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 4.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 5.  Psychosis.

Authors:  David B Arciniegas
Journal:  Continuum (Minneap Minn)       Date:  2015-06

6.  Behavioral management in the person with dementia.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2013-01       Impact factor: 4.075

7.  The Efficacy of High- or Low-Frequency Transcranial Magnetic Stimulation in Alzheimer's Disease Patients with Behavioral and Psychological Symptoms of Dementia.

Authors:  Wei Jiang; Zhenxia Wu; Li Wen; Liu Sun; Meiqun Zhou; Xiaochen Jiang; Yaxing Gui
Journal:  Adv Ther       Date:  2021-10-29       Impact factor: 3.845

8.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

Review 9.  Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.

Authors:  Jeffrey Cummings; Te-Jen Lai; Solaphat Hemrungrojn; E Mohandas; Sang Yun Kim; Girish Nair; Amitabh Dash
Journal:  CNS Neurosci Ther       Date:  2016-01-18       Impact factor: 5.243

10.  The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization.

Authors:  Milena Moretti; Michele Zoli; Andrew A George; Ronald J Lukas; Francesco Pistillo; Uwe Maskos; Paul Whiteaker; Cecilia Gotti
Journal:  Mol Pharmacol       Date:  2014-07-07       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.